Clinical Features Associated With Malignant Transformation of Low‐Grade Dysplasia
Journal of Oral Pathology & Medicine · 2026
DOI: 10.1111/jop.70070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oral Pathology & Medicine, 2026. Verfasst von Denise M Laronde und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oral Biological and Medical Science, Faculty of Dentistry, University of British Columbia, Vancouver, Canada. Hauptthemen laut MEDLINE: Cell Transformation, Neoplastic, Mouth Neoplasms, Precancerous Conditions, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCR NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Inferring risk for malignant transformation ( MT ) in patients with lesions diagnosed as mild or moderate oral epithelial dysplasia (low‐grade OED ) remains challenging. We developed two models assessing the risk of progression to high‐grade OED (severe dysplasia or carcinoma in situ) or OSCC in patients with low‐grade OED lesions.
Methods
We included demographic, risk habit and clinical data from participants with low‐grade OED lesions enrolled in the BC Oral Cancer Prevention Program's Oral Cancer Prediction Longitudinal study. Cox proportional hazard models were fit to estimate the effects of anatomic site and toluidine blue findings and adjusted for confounders, as both are associated with MT in the literature but without a North American‐specific cohort analysis. Our primary model included both variables of interest. A secondary model included only anatomic site since toluidine blue is not in widespread use.
Results
Five hundred and thirty‐four participants with 605 lesions met final inclusion criteria, with 339 mild and 266 moderate OED at baseline. In the primary model, lesions at a high‐risk anatomic site or with positive toluidine blue staining were associated with a 2.6 and 2.4‐fold increased risk of progression, respectively. In the second model that did not incorporate toluidine blue, high‐risk anatomic site remained a highly associated risk factor (2.7‐fold increased risk of progression).
Conclusion
Lesion anatomic site is associated with higher risk of MT for the general practitioner, while a specialist with access to toluidine blue results can assume additional risk associated with positive staining. These models may inform decisions for surveillance and intervention for OED .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oral Biological and Medical Science, Faculty of Dentistry, University of British Columbia, Vancouver, Canada.
- Cancer Control Research, British Columbia Cancer Research Institute, Vancouver, Canada.
- Statistics and Actuarial Science, Simon Fraser University, Burnaby, Canada.
- Department of Oral and Maxillofacial Pathology, Radiology, and Medicine, New York University College of Dentistry, New York, New York, USA.
- Department of Population Health, New York University Grossman School of Medicine, New York, New York, USA.
- Department of Radiology, New York University Grossman School of Medicine, New York, New York, USA.
ORCID-Profile: Mutita Siriruchatanon
Förderung
- NIDCR NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Laronde, D. M., Berkowitz, M., Kerr, A. R., Hade, E. M., Siriruchatanon, M., Rosin, M. P., & Kang, S. K. (2026). Clinical Features Associated With Malignant Transformation of Low‐Grade Dysplasia. Journal of Oral Pathology & Medicine. https://doi.org/10.1111/jop.70070
Vancouver
Laronde DM, Berkowitz M, Kerr AR, Hade EM, Siriruchatanon M, Rosin MP, et al. Clinical Features Associated With Malignant Transformation of Low‐Grade Dysplasia. Journal of Oral Pathology & Medicine. 2026. doi:10.1111/jop.70070
BibTeX
@article{Laronde2026,
author = {Laronde, Denise M and Berkowitz, Matt and Kerr, A Ross and Hade, Erinn M and Siriruchatanon, Mutita and Rosin, Miriam P and Kang, Stella K},
title = {Clinical Features Associated With Malignant Transformation of Low‐Grade Dysplasia},
journal = {Journal of Oral Pathology & Medicine},
year = {2026},
doi = {10.1111/jop.70070}
}
EUVIMED